Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy

European Journal of Cancer

Volumn 55, Issue , 2016, Pages 7-14

  Tokito, Takaaki ^a   Azuma, Koichi ^a   Kawahara, Akihiko ^b   Ishii, Hidenobu ^a   Yamada, Kazuhiko ^a   Matsuo, Norikazu ^a   Kinoshita, Takashi ^a   Mizukami, Naohisa ^c   Ono, Hirofumi ^c   Kage, Masayoshi ^b   Hoshino, Tomoaki ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY HOSPITAL   (Japan)

^c Yame General Hospital   (Japan)

Author keywords

CD8+ TIL; chemoradiotherapy; immunohistochemistry; non small cell lung cancer; PD L1

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CD8 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CELL DENSITY; CHEMORADIOTHERAPY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CD8+ T LYMPHOCYTE; CHEMISTRY; DISEASE FREE SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CD8-POSITIVE T-LYMPHOCYTES; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84954538129     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.11.020     Document Type: Article

References (38)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics CA Cancer J Clin 62 2012 10 29
2. A.W. Blackstock, and R. Govindan Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer J Clin Oncol 25 2007 4146 4152
3. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology: non-small cell lung cancer 2014 NCCN Fort Washington, PA
4. Y. Segawa, K. Kiura, N. Takigawa, H. Kamei, S. Harita, S. Hiraki, and et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007 J Clin Oncol 28 2010 3299 3306
5. N. Yamamoto, K. Nakagawa, Y. Nishimura, K. Tsujino, M. Satouchi, S. Kudo, and et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105 J Clin Oncol 28 2010 3739 3745
6. H. Horinouchi, I. Sekine, M. Sumi, K. Noda, K. Goto, K. Mori, and et al. Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer Cancer Sci 104 2013 93 97
7. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 2012 252 264
8. J.R. Brahmer, S.S. Tykodi, L.Q.M. Chow, W.J. Hwu, S.L. Topalian, P. Hwu, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
9. N.A. Rizvi, J. Mazières, D. Planchard, T.E. Stinchcombe, G.K. Dy, S.J. Antonia, and et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Lancet Oncol 16 2015 257 265
10. E.B. Garon, N.A. Rizvi, R. Hui, N. Leighl, A.S. Balmanoukian, J.P. Eder, and et al. Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 2015 2018 2028
11. J.R. Brahmer Harnessing the immune system for the treatment of non-small-cell lung cancer J Clin Oncol 31 2013 1021 1028
12. O. Hamid, H. Schmidt, A. Nissan, L. Ridolfi, S. Aamdal, J. Hansson, and et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma J Transl Med 9 2011 204
13. M. Sznol, and L. Chen Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer Clin Cancer Res 19 2013 1021 1034
14. R.S. Herbst, J.C. Soria, M. Kowanetz, G.D. Fine, O. Hamid, M.S. Gordon, and et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 2014 563 567
15. J. Brrahmer, K.L. Reckamp, P. Baas, L. Crinò, W.E. Eberhardt, E. Poddubskawa, and et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl Med 373 2015 123 135
16. L.H. Schmidt, A. Kümmel, D. Görlich, M. Mohr, S. Bröckling, J.H. Mikesch, and et al. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups PLoS One 10 2015 e0136023
17. J. Konishi, K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-Akita, and M. Nishimura B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression Clin Cancer Res 10 2004 5094 5100
18. J.M. Boland, E.D. Kwon, S.M. Harrington, J.A. Wampfler, H. Tang, P. Yang, and et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung Clin Lung Cancer 14 2013 157 163
19. C.-Y. Mu, J.-A. Huang, Y. Chen, C. Chen, and X.G. Zhang High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation Med Oncol 28 2011 682 688
20. Y.B. Chen, C.Y. Mu, and J.A. Huang Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study Tumori 98 2012 751 755
21. Y. Zhang, L. Wang, Y. Li, Y. Pan, R. Wang, H. Hu, and et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma Onco Targets and Therapy 7 2014 567 573
22. V. Velcheti, K.A. Schalper, D.E. Carvajai, V.K. Anagnostou, K.N. Syrigos, M. Sznol, and et al. Programmed death ligand-1 expression in non-small cell lung cancer Lab Invest 94 2014 107 116
23. J.R. Brahmer, C.G. Drake, I. Wollner, J.D. Powderly, J. Picus, W.H. Sharfman, and et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167 3175
24. J.M. Taube, R.A. Anders, G.D. Young, H. Xu, R. Sharma, T.L. McMiller, and et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci Transl Med 4 2012 127ra37
25. S.L. Topalian, C.G. Drake, and D.M. Pardoll Immune checkpoint blockade: a common denominator approach to cancer therapy Cancer Cell 27 2015 450 461
26. M. Barry, and R.C. Bleackley Cytotoxic T lymphocytes: all roads lead to death Nat Rev Immunol 2 2002 401 409
27. W.H. Fridman, F. Pages, C. Sautes-Fridman, and J. Garon The immune contexture in human tumours: impact on clinical outcome Nat Rev Cancer 12 2012 298 306
28. K.I. Al-Shibli, T. Donnem, S. Al-Saad, M. Persson, R.M. Bremnes, and L.T. Busund Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer Clin Cancer Res 14 2008 5220 5227
29. M.C. Dieu-Nosjean, M. Antoine, C. Danel, D. Heudes, M. Wislez, V. Poulot, and et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures J Clin Oncol 26 2008 4410 4417
30. K. Hiraoka, M. Miyamoto, Y. Cho, M. Suzuoki, T. Oshikiri, Y. Nakakubo, and et al. Concurrent infiltration by CD8t T cells and CD4t T cells is a favourable prognostic factor in non-small-cell lung carcinoma Br J Cancer 94 2006 275 280
31. O. Kawai, G. Ishii, K. Kubota, Y. Murata, Y. Naito, T. Mizuno, and et al. Predominant infiltration of macrophages and CD8(t) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer Cancer 113 2008 1387 1395
32. K.A. Schalper, J. Brown, D. Carvajal-Hausdorf, J. McLaughlin, V. Velcheti, K.N. Syrigos, and et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer JNCI J Natl Cancer Inst 107 2015 dju435
33. + T-cell density - a promising supplement to TNM staging in non-small cell lung cancer Clin Cancer Res 21 2015 2635 2643
34. M.H. Kershaw, M.W. Teng, M.J. Smyth, and P.K. Dancy Supernatural T cells: genetic modification of T cells for cancer therapy Nat Rev Immunol 5 2005 928 940
35. M.K. Young, J. Koh, H. Go, H. Go, Y.K. Jeon, and D.H. Chung Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers Lung Cancer 88 2015 24 33
36. M.F. Sanmamed, and L. Chen Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation Cancer J 20 2014 256 261
37. Y. Zhang, S. Huang, D. Gong, Y. Qin, and Q. Shen Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer Cell Mol Immunol 7 2010 389 395
38. J. Galon, B. Mlecnik, G. Bindea, H.K. Angell, A. Berger, C. Lagorce, and et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours J Pathol 232 2014 199 209